These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2533899)

  • 41. Delayed diagnosis of anaphylaxis secondary to ondansetron: A case report.
    Goyal P; Paramesh K; Puranik S; Proctor M; Sanghvi M
    Eur J Anaesthesiol; 2016 Feb; 33(2):146-7. PubMed ID: 26555872
    [No Abstract]   [Full Text] [Related]  

  • 42. Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event.
    Lebrun C; Chichmanian RM; Peyrade F; Chatel M; Frenay M
    Ann Oncol; 1997 Sep; 8(9):919-20. PubMed ID: 9358948
    [No Abstract]   [Full Text] [Related]  

  • 43. Enzyme-linked immunosorbent assay for ondansetron captured from airborne samples.
    Hreczuk-Hirst D; Rowell FJ; Reeve RN; Cumming RH; Guest I
    Analyst; 1998 May; 123(5):1121-6. PubMed ID: 9709495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ondansetron in carcinoid syndrome.
    Jacobsen MB
    Lancet; 1992 Jul; 340(8812):185. PubMed ID: 1352604
    [No Abstract]   [Full Text] [Related]  

  • 45. Ondansetron: pharmacology of a specific 5HT3-receptor antagonist.
    Deegan R
    Am J Med Sci; 1992 Dec; 304(6):373-8. PubMed ID: 1456277
    [No Abstract]   [Full Text] [Related]  

  • 46. Ondansetron in carcinoid syndrome.
    Platt AJ; Heddle RM; Rake MO; Smedley H
    Lancet; 1992 Jun; 339(8806):1416. PubMed ID: 1375972
    [No Abstract]   [Full Text] [Related]  

  • 47. Ondansetron and headache.
    Shuster J
    Nursing; 1999 Jan; 29(1):66. PubMed ID: 9987303
    [No Abstract]   [Full Text] [Related]  

  • 48. An extrapyramidal reaction to ondansetron.
    Stonell C
    Br J Anaesth; 1998 Oct; 81(4):658. PubMed ID: 9924258
    [No Abstract]   [Full Text] [Related]  

  • 49. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture.
    Kirkham JC; Rutherford ET; Cunningham GN; Daneshmand KA; Falls AL
    Am J Health Syst Pharm; 1995 Jul; 52(14):1557-8. PubMed ID: 7552902
    [No Abstract]   [Full Text] [Related]  

  • 50. Is ondansetron "too expensive"?
    Pannuti F; Tanneberger S; Lelli G; Piana E
    Lancet; 1992 Mar; 339(8793):614-5. PubMed ID: 1347112
    [No Abstract]   [Full Text] [Related]  

  • 51. Discoloration of parenteral ondansetron.
    H Tsui BC; Cave D
    Anesth Analg; 2003 Apr; 96(4):1239. PubMed ID: 12651705
    [No Abstract]   [Full Text] [Related]  

  • 52. Critique of inaccurate reporting in Edlavitch article on "Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication".
    Fejzo MS; MacGibbon KW; Mullin PM
    Reprod Toxicol; 2018 Jan; 75():144-145. PubMed ID: 29174065
    [No Abstract]   [Full Text] [Related]  

  • 53. Reply.
    Gummin DD; Moeller JR; Drendel AL
    J Pediatr; 2017 Sep; 188():312-313. PubMed ID: 28571711
    [No Abstract]   [Full Text] [Related]  

  • 54. Ondansetron clinical pharmacokinetics.
    Roila F; Del Favero A
    Clin Pharmacokinet; 1995 Aug; 29(2):95-109. PubMed ID: 7586904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
    de Wit R; Beijnen JH; van Tellingen O; Schellens JH; de Boer-Dennert M; Verweij J
    Br J Cancer; 1996 Jul; 74(2):323-6. PubMed ID: 8688345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
    Markham A; Sorkin EM
    Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
    Tramèr MR; Reynolds DJ; Moore RA; McQuay HJ
    Anesthesiology; 1997 Dec; 87(6):1277-89. PubMed ID: 9416710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy of prophylactic protocols in reducing perioperative nausea and vomiting during video-assisted thoracoscopic radical resection of lung cancer.
    Zhang W; Shen Z; Jiang J; Zhu S; Zhang P; Chen S; Kang M
    Sci Rep; 2024 Apr; 14(1):9818. PubMed ID: 38684769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov.
    Ashour AM
    Front Pharmacol; 2023; 14():1310455. PubMed ID: 38074143
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacological Agents Affecting Emesis : A Review (Part II).
    Mitchelson F
    Drugs; 1992 Apr; 43(4):443-463. PubMed ID: 28421555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.